# Proteint

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/proteint

- Industry: Biotechnology
- Headquarters: Tianjin, China
- Website: www.proteint.com
- Total disclosed funding: $15M
- Latest round: Series A (Jan 28, 2023)
- Investors on record: 1

## About

Based in Tianjin, China, and established in 2014, Proteint is a biotechnology company that focuses on the field of multi-omics. The R&D team members are from Yale University, the National Institutes of Health, and the National Center for Protein Science, and doctoral degree account for 50%. Jie Li, the company's founder, once worked at Yale University as a researcher at the School of Medicine and a director of sample Bank at Yale Cancer Research Center. And Jie, Li, published over 70 papers in Science, Nature, and Genetics, and undertook more than 10 items of national-level science and research fund programs. And, Proteint has more than 100 software copyrights and 60 invention patents. In 2016, it established a medical testing lab. In 2018, it established a subsidiary, Proteint Nuclear Magnetics, and performed chronic disease management.  In 2019, it launched the normal range of blood lipids in Chinese people based on the sample testing volume of more than 40,000 cases. Moreover, its partners include Beijing Proteome Research Center, Bruker, Thermo Fisher Scientific, and others. 

Proteint provides multi-omics testing services for tumors and cardiology, based on three technology platforms, genomics platform, proteomics platform, and metabolomics platform. The genomics platform is equipped with Illumina NextSeq 500 sequencing systems, and automated second-generation sequencing platforms, which can test 2,000 anti-tumors drugs related genetic mutations, and also provides exome sequencing products, 1421 gene test products, 430 gene test products, and 127 gene test products. It also provides chronic disease management solutions, based on the nuclear magnetic resonance spectroscopy platforms, including early warning of cardiovascular disease, lipid-regulating drug selection and monitoring, and health testing of the six major metabolic systems of the human body.

## Funding rounds

- Series A, Jan 28, 2023, $15M — CDH Baifu Capital

## Investors

- CDH Baifu Capital (https://capitalatlas.ai/funds/cdh-baifu-capital) — Series A